Artrya Ltd (ASX: AYA) shares are starting the week with a bang.
In morning trade, the ASX AI share is up over 11% to $3.85.
Image source: Getty Images
Why is this ASX AI share jumping?
Investors have been bidding the company's shares higher today after it secured its second customer in the United States.
According to the release, Artrya, which is a medical technology company commercialising its Salix AI-powered cloud platform, has signed a commercial agreement with Northeast Georgia Health System.
Management believes this marks another significant milestone in the company's accelerating U.S. expansion strategy.
The Salix AI-powered cloud platform is used for the near real time, point of care assessment and management of coronary artery disease.
The release notes that the three-year commercial agreement has a minimum value of US$0.3 million, with additional fee-per-scan revenue from the Salix Coronary Plaque module and, following FDA clearance, the Salix Coronary Flow module.
The Salix platform will be rolled out across Northeast Georgia Health System's network of hospitals and used by its cardiology group, Georgia Heart Institute.
Commenting on the news, the ASX AI share's co-founder and CEO, John Konstantopoulos, said:
We are proud to secure our second U.S. commercial customer through this three-year commercial agreement with Northeast Georgia Health System, a respected leader in patient care across the U.S. Southeast. This builds our longstanding partnership to validate Salix in their workflow, and we are excited to roll out Salix across the Northeast Georgia Health System network.
We remain on track to convert all three U.S. foundation partners to commercial customers this year, where our new Customer Success team is already playing a leading role in integration and support.
Georgia Heart Institute's chief cardiology officer, Mudassar Ahmed, MD, MBA, spoke positively about the deal, commenting:
The Salix platform will now go live in our clinical workflow, which represents an important step forward in how we deliver cardiovascular care. At Georgia Heart Institute, we are committed to adopting technologies that not only enhance diagnostic precision but also transform the patient journey. Through our work during the past two years, we have seen that Salix can bring a new dimension to our practice by supporting earlier identification of risk and enabling more proactive treatment strategies.
To support its growing U.S. customer base and anticipated expansion, the ASX AI share has established a customer success team in Atlanta. It notes that this team will serve as a technology and support hub, providing technical integration expertise, clinician engagement, and comprehensive customer support on the ground.
